Pneumococcal Disease: Recommended vaccinations
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 
Vaccination not funded by the National Health system
 
Mandatory vaccination
MonthsYears
123456101112131415182325618195060646585≥ 86
Austria
PCV
PCV
PCV1
PCV132
Belgium
PCV
PCV
PCV
PCV133
PCV134
Bulgaria
PCV
PCV
PCV
PCV5
Croatia
Cyprus
PCV
PCV
PCV6
PPSV237
PPSV238
Czech Republic
PCV9
PCV9
PCV9
Pnc10
Pnc11
Denmark
PCV13
PCV13
PCV13
PPSV2312
Estonia
Finland
PCV10
PCV10
PCV10
PCV13+PPSV2313
France
PCV
PCV
PCV
Germany
PCV
PCV
PCV
PCV14
PPSV2315
Greece
PCV13
PCV13
PCV13
PCV13
PCV13
PCV13+PPSV23
PCV13+PPSV23
PCV13+PPSV23
Hungary
PCV13
PCV13
PCV13
PPSV23
Iceland
PCV10
PCV10
PCV10
PPSV2316
Ireland
PCV
PCV
PCV
PPSV2317
Italy
PCV
PCV
PCV
PCV13+PPSV2318
Latvia
PCV
PCV
PCV
Liechtenstein
PCV1319
PCV1319
PCV1319
Lithuania
PCV
PCV
PCV20
Luxembourg
PCV
PCV
PCV
PCV
PPSV2321
PCV13+PPSV2321
Malta
PCV
Netherlands
PCV22
PCV
PCV
Norway
PCV13
PCV13
PCV13
PPSV2323
Poland
PCV
PCV
PCV
PCV
Portugal
PCV13
PCV13
PCV13
Romania
PCV24
PCV24
PCV24
Slovakia
PCV
PCV
PCV
PCV25
Slovenia
PCV
PCV
PCV
PPSV2326
Spain
PCV27
PCV27
PCV27
PPSV2328
Sweden
PCV
PCV
PCV
PPSV23
United Kingdom
PCV13
PCV13
PCV13
PPSV23

Footnotes:

  1. Minimum interval of 6 month after second dose
  2. If no previous vaccination, 1 dose of PPSV23 after one year. If previous vaccination with PPSV23, 1 dose of PCV13 2 years later.If previous dose of PCV13, 1 dose of PPSV23 2 year later.
  3. Pneumococcal vaccination is recommended in healthy adults from 65 to 85 years, in adults with comorbidity from 50 to 85 years, and in adults with an increased risk of invasive pneumococcal infection from 19 to 85 years. These target patients (comorbidity and adults with an increased risk of IPD) are specifically identified in the corresponding recommendations (https://www.health.belgium.be/fr/avis-9210-vaccination-antipneumococcique-adultes-fiche). Vaccine schedule for complete primo-vaccination: a single dose of PCV13, followed by PPSV23 after at least 8 weeks. If vaccination in the past with PPSV23, a single dose of PCV13 at least one year after the last PPSV23 vaccine. Booster vaccination with PPSV23 every 5 years is recommended for adults with an increased risk of IPD. Indication for a booster vaccination for the other adult risk groups should be evaluated based on the latest evidence-based data and epidemiology.
  4. Adults over 85 years: : indication for pneumococcal vaccination should be decided on an individual basis, taking into account the individual risk of pneumococcal infection and the expected/estimated immune response to the vaccine. The vaccine schedule is the same as that recommended for the other adult target groups (https://www.health.belgium.be/fr/avis-9210-vaccination-antipneumococcique-adultes-fiche).
  5. Not earlier than 6 months after the 3rd dose
  6. catch-up possible until 6 years if previous recommended doses were missed
  7. vaccines only given on specific indications
  8. no revaccination recommended
  9. Recommendation only, the vaccination is covered by the health insurance
  10. PCV for people hospitalized at long-term-illness wards and houses for seniors. Also for at-risk groups of people based in houses for people with health disability and houses with special regime.
  11. PCV for persons from 65 years of age. Recommended only. The vaccination is covered by the health insurance.
  12. PCV 13 also recommended. For recommendations from Statens Serum Institut for vaccination of people within at-risk groups refer to http://www.ssi.dk/English/News/EPI-NEWS/2014/No%2040%20-%202014.aspx. There are no official recommendations from the Danish Health and Medicines Authority for use of PPV23 or PCV 13, but there is, however, reimbursement for defined at-risk groups.
  13. Recommended but not free of charge for those over 65 years. For more information on pneumococcal vaccination policy please refer to http://www.thl.fi/fi_FI/web/rokottajankasikirja-fi/pneumokokkikonjugaattirokotukset
  14. number of doses necessary varies according to age
  15. one dose recommended, booster doses every 6 years if indicated
  16. One dose is recommended for all adults over age 60. For risk groups one dose of conjugated vaccine and one dose of PPS vaccine is recommended after 2 years of age . for more information see: https://www.landlaeknir.is/servlet/file/store93/item23265/Lei%C3%B0beiningar%20um%20notkun_b%C3%B3luefna_gegn_pneum%C3%B3kokkum-final.pdf
  17. The vaccine is free of charge, but administration fees may be charged to patient (based on income and eligibility for free healthcare)
  18. one dose of PCV13 at 65 years and one dose PPSV after at least 8 weeks
  19. not part of the basic vaccination plan
  20. Can be administered concomitantly with MMR
  21. It is recommended that populations at risk and elderly 65 years of age and over receive a dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed, 8 weeks later, by a dose of 23-valent pneumococcal polysaccharide vaccine (PCV23). In the present state of knowledge, the CSMI recommends a PPV23 recall only in people at risk, who are recalled every 5 years. Children at risk of invasive pneumococcal infection are also affected by this recommendation: in the absence of previous vaccination with PCV13, catch-up is indicated. For mopre informeation: http://www.sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/infection-pneumocoques/index.html
  22. Should be given at 6-9 weeks
  23. One dose if not vaccinated in the previous 10 years. Reimbursed for some at-risk groups.
  24. Pneumococcal conjugate vaccine will be included in the national vaccination calendar depending on available funds
  25. Recommended to all. Mandatory to persons residing in social care facilities
  26. PCV13 can be used. self-paid. further information on pneumococcal disease vaccination policy available at http://www.ivz.si/cepljenje/strokovna_javnost/navodila_in_priporocila?pi=18&_18_view=item&_18_newsid=2230&pl=253-18.0.
  27. Children over 5 years of age and adults with high risk conditions should receive PCV13. Please refer to http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Neumococo_Gruposriesgo.pdf
  28. Those with high risk conditions (asplenia, chronic kidney disease, nefrotic syndrome and immunosupresion) should receive PCV13 two months before PPSV23. Please refer to http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Neumococo_Gruposriesgo.pdf